Biotechnology company Neptune Technologies & Bioresources, Inc. announced it has received “New Food Raw Material” certification in China. This enables the company to sell its krill oil nutraceutical products in China, including NKO, its premium krill oil, and EKO, its eco krill oil. China’s National Health and Family Planning Commission found no quality or safety concerns, which affirms the strength of Neptune’s products.
China, with its population of more than 1.35 billion people, offers significant growth potential for Neptune. The consumer demand for nutraceutical products that support health and wellness continues to increase in China, and the company plans to capitalize on this important market. Neptune already has sales representation in China and is actively pursuing sales opportunities.
Chiefly engaged in developing and commercializing marine-derived omega-3 polyunsaturated fatty acids (PUFAs), Neptune has patented a process for extracting oils from Antarctic krill. The company principally sells omega-3 PUFAs as bulk oil to its distributors, who then commercialize them under private labels mainly in the U.S., European and Australian nutraceutical markets. Serving as a dietary supplement to consumers, Neptune’s products generally come in bulk oil or capsule form.
Through its 49.95 percent voting rights in Acasti and its 96 percent voting rights in NeuroBioPharm, Inc., Neptune is additionally pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio are respectively focused on researching and developing safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions as well as neurodegenerative and inflammation-related conditions. Acasti’s lead prescription drug candidate is CaPre, which is a purified high omega-3 phospholipid concentrate derived from Neptune krill oil. CaPre is being developed to address the prevention and treatment of cardiometabolic disorders.
For more information, visit Neptune’s website at www.neptunebiotech.com
Let us hear your thoughts below: